Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidy

Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]   

The glycomic therapeutics market in the Middle East & Africa is expected to grow from US$ 5,785.63 million in 2022 to US$ 12,853.18 million by 2028; it is estimated to grow at a CAGR of 13.1% from 2022 to 2028.

New Tools in Glycomics Research to Drive Market Growth

Glycomics has the potential to pave the way for innovative treatment approaches by enhancing the characterization of molecules crucial for the development of diseases. It can be a substantial addition to technologies used in genomes and proteomics. Comparative glycomics will be essential for identifying the glycans that cause the disease. There is a rising number of studies that will provide vital information on the relationship between clinical outcomes and glycomic anomalies. Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have been used to distinguish cell populations using glycoproteins. These are among the important technologies utilized to advance glycomics. LC-MS can provide structural details about glycoconjugates by separating several glycoprotein isoforms from a single protein species. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics.

Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures. Identification of disease-related glycoconjugates by LC-MC, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to assess or validate IHC. Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC. It will be possible to witness new aspects of glycomics, such as thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, including glycolipids. Tandem or multi-technology procedures, such as MS-IHC, would provide the analytical ability to labs to handle the glycoconjugates complexity and improve glycoconjugate diagnosis. The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies. Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and provides knowledge to researchers and doctors regarding illness. Owing to the rising scientific discoveries, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind glycomic therapeutics is adequate and that the practice of medicine is evidence-based.

Growing evidence of glycomics role in human health highlights the need to integrate glycomics into precision medicine. Cell surface expression of glycoconjugates determines in vivo recognition and in vitro interactions. Microorganisms that perform important functions for their hosts, such as food digestion and vitamin synthesis and absorption, utilize complex carbohydrates to tell immune cells that they are not harmful. Pathogens that cause deadly diseases, such as tuberculosis and malaria, use similar strategies to evade attacks by the immune system.

Market Overview



The UAE, Saudi Arabia, and South Africa are the three major countries in the Middle East & South Africa. Saudi Arabia was the largest market for glycomic therapeutics in this region in 2022. The market for glycomic therapeutics in the Middle East & Africa is anticipated to grow at a CAGR of 14.2% during the forecast period; this growth is attributed to the rising prevalence of cancer and metabolic diseases and increasing government initiatives in terms of funding and healthcare-related policies.

Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Middle East & Africa Glycomic Therapeutics Market Segmentation

The Middle East & Africa glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Middle East & Africa glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Middle East & Africa glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Middle East & Africa glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Middle East & Africa glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Middle East & Africa glycomic therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022. Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in the Middle East & Africa.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa Glycomic Therapeutics Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.